search
Back to results

GSL Synthetase Inhibitor or in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

Primary Purpose

Solid Tumor, Hematologic Malignancy

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Eliglustat
Immune checkpoint inhibitor
Sponsored by
Chinese PLA General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumor focused on measuring GSL synthetase inhibitor, Immune checkpoint inhibitor, Solid tumor, Hematologic Malignancy

Eligibility Criteria

16 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age from 16 to 75 years with estimated life expectancy >3 months.
  2. Histopathological confirmed advanced or metastatic systematically pretreated solid tumors and relapsed/refractory hematological malignancies.
  3. Have at least one measurable target lesion for solid tumors.
  4. Fresh solid tumor samples or formalin-fixed paraffin embedded tumor archival samples within 3 months are necessary; Fresh tumor samples are preferred. Subjects are willing to accept tumor re-biopsy in the process of this study.
  5. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to <= grade 1 toxicity.
  6. Have an Eastern Cooperative Oncology Group performance status (ECOG) of 0 or 2 at the time of enrollment.
  7. Have adequate organ function, which should be confirmed within 2 weeks prior to the first dose of study drugs.
  8. Previous treatment with anti-PD-1/PD-L1 antibodies or cytotoxic T lymphocyte associated antigen 4 (CTLA-4) inhibitors are allowed.
  9. Ability to understand and sign a written informed consent document.
  10. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and up to 90 days after the last dose of the drug.

Exclusion Criteria:

  1. Patients are unwilling to comply with the requirements of the protocol.
  2. The patient has documented prior esophageal varices or liver infarction or current liver enzymes (alanine transaminase, aspartate aminotransferase) or total bilirubin >3 times the upper limit of normal.
  3. The patient is known to have any of the following: cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, current treatment with Class IA or Class III antiarrhythmic medicinal products, interstitial lung disease of any grade or severely impaired pulmonary function.
  4. Uncontrolled intercurrent illness, including ongoing or active systemic infection or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient.
  5. The patients is taking a CYP2D6 inhibitor and/or concomitantly with a strong or moderate CYP3A inhibitor.
  6. Active, known or suspected autoimmune diseases.
  7. Known brain metastases or active central nervous system (CNS). Subjects with CNS metastases who were treated with radiotherapy for at least 3 months prior to enrollment, have no central nervous symptoms and are off corticosteroids, are eligible for enrollment, but require a brain MRI screening.
  8. Patients are being treated with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment.
  9. History of severe hypersensitive reactions to other monoclonal antibodies.
  10. History of allergy or intolerance to study drug components.
  11. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
  12. History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
  13. Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented.
  14. Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].
  15. Vaccination within 30 days of study enrollment.
  16. Active bleeding or known hemorrhagic tendency.
  17. Subjects with unhealed surgical wounds for more than 30 days.
  18. Being participating any other trials or withdraw within 4 weeks.

Sites / Locations

  • Department of Biotherapeutic, Chinese PLA General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Experimental Arm A

Experimental Arm B

Arm Description

Eliglustat 84mg will be administered once daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be daily administered every other week to 96 weeks. Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks.

Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), or intermediate metabolizers (IMs), or in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks. Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks.

Outcomes

Primary Outcome Measures

Number of subjects occuring treatment related adverse events
Determining the safety profile following the initiation of treatment and grading these toxicities by CTCAE v5.0

Secondary Outcome Measures

The percentage of enrolled patients that respond to the treatment
Overall response rate is defined as the sum of partial responses and complete responses

Full Information

First Posted
June 23, 2021
Last Updated
April 28, 2022
Sponsor
Chinese PLA General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04944888
Brief Title
GSL Synthetase Inhibitor or in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Official Title
Phase ⅠStudy of GSL Synthetase Inhibitor Monotherapy or in Combination With Immune Checkpoint Inhibitor in Treating Patients With Advanced Relapsed or Refractory Hematological Malignancies and Previously Treated Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2021 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese PLA General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Immune checkpoint blockade has made great but unsatisfied success in treating cancers. One important reason is the hijacked HLA (Human Leukocyte Antigen) antigen presentation. Eliglustat could inhibit glycosphingolipids synthesis and restore HLA-I antigen presentation and transform the immunogenicity of tumor cells. Therefore,GSL synthetase inhibitor eliglustat monotherapy or in combination with immune checkpoint inhibitor may explore a new avenue for therapeutic intervention in cancer.
Detailed Description
Immune checkpoint blockade has led to great strides in the management of various cancers, however, durable response could be seen in approximately 20% of treated patients with most solid tumors and hematological malignancies. One important reason is that tumor cells often escape from immune surveillance by downregulating one or multiple molecules critical in HLA antigen presentation. As a consequence, options that could restore HLA antigen presentation may augment immune checkpoint inhibitor-mediated immune responses. Abnormal expression of glycosphingolipid (GSL) synthetase is a basic and specific characteristic of most tumors and tumor microenvironment, such as Globo H Ceramide, which is overexpressed in multiple epithelial-derived tumors. Several studies also reported that GSL synthetase was overexpressed in chemotherapy-resistant tumors. Eliglustat is an orally GlcCer synthase inhibitor, which is approved for treating Type-1 Gaucher disease. However, one most recent study reveals that it could inhibit glycosphingolipids synthesis and restore HLA antigen presentation, and transforming the immunogenicity of tumor cells. Therefore, GSL synthetase inhibitor eliglustat monotherapy or in combination with immune checkpoint inhibitor may explore a new avenue for therapeutic intervention in cancer. The primary objective of this study is to assess the safety and feasibility of GSL synthetase inhibitor eliglustat monotherapy or in combination with immune checkpoint inhibitor in patients with relapsed or refractory hematological malignancies and solid tumors. The secondary objectives include assessing antitumor activity, pharmacokinetics and pharmacodynamics. The exploratory objectives are to evaluate the pathological, immunological or clinical predictive biomarkers for efficacy and toxicity, transformation of tumor microenvironment and dynamic changes of immune cells in peripheral blood.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor, Hematologic Malignancy
Keywords
GSL synthetase inhibitor, Immune checkpoint inhibitor, Solid tumor, Hematologic Malignancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Arm A
Arm Type
Experimental
Arm Description
Eliglustat 84mg will be administered once daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs), in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be daily administered every other week to 96 weeks. Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks.
Arm Title
Experimental Arm B
Arm Type
Experimental
Arm Description
Eliglustat 84mg will be administered twice daily in patients who are CYP2D6 ultra-rapid metabolizers (URMs), extensive metabolizers (EMs), or intermediate metabolizers (IMs), or in the first 14 days and the following every other week until 24 weeks. For patients who still benefit from the trial, eliglustat 84mg will be administered twice daily every other week to 96 weeks. Immune checkpoint inhibitor (physician decided) will be administered intravenously on day 5 or day 15 every 3 weeks. For patients who still benefit from the trial, immune checkpoint inhibitor will be administered every 3 week to 96 weeks.
Intervention Type
Drug
Intervention Name(s)
Eliglustat
Intervention Description
Eliglustat, 84mg daily or 84mg twice daily; Enrolled patients will be assigned to Arm A and Arm B, respectively.
Intervention Type
Drug
Intervention Name(s)
Immune checkpoint inhibitor
Intervention Description
immune checkpoint inhibitor (physician decided).
Primary Outcome Measure Information:
Title
Number of subjects occuring treatment related adverse events
Description
Determining the safety profile following the initiation of treatment and grading these toxicities by CTCAE v5.0
Time Frame
Up to 90 days after the last dose of study drugs.
Secondary Outcome Measure Information:
Title
The percentage of enrolled patients that respond to the treatment
Description
Overall response rate is defined as the sum of partial responses and complete responses
Time Frame
Up to 120 days after the last dose of study drugs
Other Pre-specified Outcome Measures:
Title
Immunological response (cytokines, lymphocyte phenotype)
Description
Immunological responses, including the concentration of cytokines in tumor beds and peripheral blood and the changes of lymphocyte phenotype following the treatment, will be assessed by qPCR and flow cytometer.
Time Frame
Up to 120 days after the last dose of study drugs
Title
Biomarkers predictive of response and toxicity
Description
Biomarkers from tumor cells, lymphocytes and tumor microenvironment will be assessed for their potential in predicting clinical response and toxicity.
Time Frame
Up to 120 days after the last dose of study drugs

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age from 16 to 75 years with estimated life expectancy >3 months. Histopathological confirmed advanced or metastatic systematically pretreated solid tumors and relapsed/refractory hematological malignancies. Have at least one measurable target lesion for solid tumors. Fresh solid tumor samples or formalin-fixed paraffin embedded tumor archival samples within 3 months are necessary; Fresh tumor samples are preferred. Subjects are willing to accept tumor re-biopsy in the process of this study. Previous treatment must be completed for more than 4 weeks prior to the enrollment of this study, and subjects have recovered to <= grade 1 toxicity. Have an Eastern Cooperative Oncology Group performance status (ECOG) of 0 or 2 at the time of enrollment. Have adequate organ function, which should be confirmed within 2 weeks prior to the first dose of study drugs. Previous treatment with anti-PD-1/PD-L1 antibodies or cytotoxic T lymphocyte associated antigen 4 (CTLA-4) inhibitors are allowed. Ability to understand and sign a written informed consent document. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and up to 90 days after the last dose of the drug. Exclusion Criteria: Patients are unwilling to comply with the requirements of the protocol. The patient has documented prior esophageal varices or liver infarction or current liver enzymes (alanine transaminase, aspartate aminotransferase) or total bilirubin >3 times the upper limit of normal. The patient is known to have any of the following: cardiac disease (congestive heart failure, recent acute myocardial infarction, bradycardia, heart block, ventricular arrhythmia), long QT syndrome, current treatment with Class IA or Class III antiarrhythmic medicinal products, interstitial lung disease of any grade or severely impaired pulmonary function. Uncontrolled intercurrent illness, including ongoing or active systemic infection or psychiatric illness/social situations and any other illness that would limit compliance with study requirements and jeopardize the safety of the patient. The patients is taking a CYP2D6 inhibitor and/or concomitantly with a strong or moderate CYP3A inhibitor. Active, known or suspected autoimmune diseases. Known brain metastases or active central nervous system (CNS). Subjects with CNS metastases who were treated with radiotherapy for at least 3 months prior to enrollment, have no central nervous symptoms and are off corticosteroids, are eligible for enrollment, but require a brain MRI screening. Patients are being treated with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. History of severe hypersensitive reactions to other monoclonal antibodies. History of allergy or intolerance to study drug components. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results. History of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS). Pregnant or breast-feeding. Women of childbearing potential must have a pregnancy test performed within 7 days before the enrollment, and a negative result must be documented. Previous or concurrent cancer within 3 years prior to treatment start EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer, superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)]. Vaccination within 30 days of study enrollment. Active bleeding or known hemorrhagic tendency. Subjects with unhealed surgical wounds for more than 30 days. Being participating any other trials or withdraw within 4 weeks.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Weidong Han, PhD
Phone
+86-10-66937463
Email
hanwdrsw69@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Kaichao Feng, MD
Phone
+86-10-66937231
Email
timothyfkc@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Weidong Han, PhD
Organizational Affiliation
Biotherapeutic Department, Chinese PLA General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Biotherapeutic, Chinese PLA General Hospital
City
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weidong Han, Ph.D
Phone
+86-10-66937463
Email
hanwdrsw@sina.com
First Name & Middle Initial & Last Name & Degree
Kaichao Feng, MD
Phone
+86-10-66937231
Email
timothyfkc@126.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

GSL Synthetase Inhibitor or in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

We'll reach out to this number within 24 hrs